Tenaya Therapeutics, Inc. (TNYA) stock
TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.31−0.02 (-4.93%)
Close on Nov 18, 2026Market cap $68.82MP/E –Yield –
Tenaya Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tenaya Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$105.86M. For fiscal 2025 it was -$93.33M. The highest annual figure on record is -$38.91M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$93.33M | – |
| FY2024 | Dec 31, 2024 | -$115.95M | – |
| FY2023 | Dec 31, 2023 | -$131.19M | – |
| FY2022 | Dec 31, 2022 | -$125.62M | – |
| FY2021 | Dec 31, 2021 | -$72.81M | – |
| FY2020 | Dec 31, 2020 | -$38.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$20.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.82M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.76M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$30.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$35.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.72M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$31.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.16M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.30M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.87M | – |
See a number that looks wrong?